

ArmaGen™ Technologies, Inc.



Biotechnology for the brain

Opportunity Overview

Opportunity: ArmaGen's proprietary Molecular Trojan Horse (MTH) technology has the potential to create druggable brain-targeted biologic therapeutics from previously undruggable drug candidates that must cross the blood brain barrier (BBB) for therapeutic efficacy.

Partnering Goals: ArmaGen's versatile Trojan horse platform technology can be applied to virtually any biologic drug development program that has identified therapeutic targets in the brain. ArmaGen is interested in exploring partnering opportunities with companies that have brain-targeted biologics that would benefit from targeted transport across the BBB using its Trojan horse technology. Potential development collaboration opportunities could include:

- Monoclonal antibodies, recombinant proteins, therapeutic enzymes, decoy receptors, and peptide development programs targeting novel disease mechanisms in the brain
- Marketed therapies that would have therapeutic potential in the brain, if the BBB drug delivery problem was solved

ArmaGen would bring to the partnership senior management with 40 years of scientific knowledge of BBB transport mechanisms, which would be applied to your drug development program.

Drug Classes and Therapeutic Areas

Brain Targeted Therapy: ArmaGen's Trojan horse platform technology has been reduced to practice with multiple classes of biopharmaceuticals for therapeutic targets located in the brain.

Drug Class	Drug	indication
Monoclonal antibody	ScFv against Abeta peptide of AD	Alzheimer's disease (AD)
Neurotrophin	Erythropoietin, GDNF	Neuro-degeneration
Decoy receptor	TNFR-II	AD, depression
Therapeutic enzyme	Iduronidase; Iduronate 2-sulfatase	Lysosomal Storage Disorders
Radiopharmaceutical	peptide or antisense	Brain imaging


Novel Therapeutics Summary

ArmaGen is developing its own pipeline of drug candidates, exemplifying how its Trojan horse technology can be applied to a variety of brain-targeted drug development programs.

Drug Candidate	Indications	Development Phase
AGT-181	MPS-I (Hurler's)	Phase 0
AGT-182	MPS-II (Hunter's)	Phase 0
AGT-115, AGT-190	Stroke Parkinson's disease	Preclinical
AGT-160	Alzheimer's disease	Preclinical
AGT-110	Alzheimer's disease	Preclinical

Technology Overview

ArmaGen's patented molecular Trojan horse technology uses endogenous Receptor Mediated Transport (RMT) to ferry drugs across the BBB. By creating new drug constructs that bind to endogenous receptors such as the human insulin receptor (HIR), located on the surface of the BBB, drug candidates previously unable to cross the BBB are easily transported.




Preclinical Studies


ArmaGen has genetically engineered molecular Trojan horses that are active in mice, Rhesus monkeys, and humans, which enables the engineering of novel fusion proteins for in vivo testing, and this expertise can be applied to your drug development programs.

Rhesus Monkey Brain Scan

DRUG ALONE



DRUG – TROJAN HORSE



Benefits of BBB Trojan horse Technology

- Address BBB issues early in the brain drug development process
- BBB molecular Trojan horses cross the BBB without barrier disruption, which avoids the toxic effects caused by brain uptake of plasma proteins
- Intravenous or subcutaneous administration without transcranial drug delivery to the brain
- Can be used with numerous drug classes, and virtually any biopharmaceutical can be re-engineered for targeted BBB delivery
- IgG fusion proteins have potential for reduced immunogenicity
- Rapid re-engineering of your biopharmaceutical for brain targeting
- Fusion of your drug to the Trojan horse creates a New Chemical Entity for extension of patent protection

Partnering Contact Information

For additional information on how ArmaGen's Molecular Trojan Horse technology can be applied to your drug development program, please contact:

Ruben J. Boado, Ph.D.

Vice-President

rboado@armagen.com

310-917-1275 (PH)

310-917-1276 (FAX)